Advertisement
Advertisement
U.S. Markets open in 5 hrs 28 mins
Advertisement
Advertisement
Advertisement
Advertisement

Advaxis, Inc. (ADXS)

Other OTC - Other OTC Delayed Price. Currency in USD
2.1000+0.1250 (+6.33%)
At close: 02:35PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9750
Open2.0000
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range1.9800 - 2.1000
52 Week Range1.0000 - 11.1840
Volume1,087
Avg. Volume6,157
Market Cap3.813M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-0.3270
Earnings DateFeb 13, 2023 - Feb 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Advaxis and Ayala Pharmaceuticals Complete Merger

    REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small

  • GlobeNewswire

    Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

    Dose escalation has been completed and enrollment at second dose level will be expanded at Columbia University ADXS-504 has been well tolerated with no serious adverse events reportedFour out of six patients treated are still on study and PSA values are being followed up MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update

  • GlobeNewswire

    Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

    Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmace

Advertisement
Advertisement